<DOC>
	<DOCNO>NCT02625558</DOCNO>
	<brief_summary>Double blind placebo control trial riociguat sarcoidosis associate pulmonary hypertension</brief_summary>
	<brief_title>Riociguat Sarcoidosis Associated Pulmonary Hypertension</brief_title>
	<detailed_description>Study design Patients recruit double blind randomize trial riociguat 1:1 active drug placebo . The table summarize study design . Patients previously undergone right heart catheterization ( RHC ) within six month initial dose dispensation significant change treatment pulmonary hypertension . Patients initiate 0.5 mg tid titrate every 2 week maximum 2.5 mg three time day . The patient treat 48 week clinical worsen disease . An adjudication committee review case clinical worsening . This committee blind treatment . The determination adjudication committee use final determinant primary end point .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<criteria>Patients diagnosis sarcoidosis Age ≥ 18 year . Life expectancy least 2 year . Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . Females reproductive potential ( FRP ) must negative , pretreatment pregnancy test . FRP must obtain monthly pregnancy test treatment one month treatment discontinuation . Postmenopausal woman ( defined menses least 1 year postsurgical bilateral oophorectomy ) surgically sterilize woman require undergo pregnancy test . Females reproductive potential nonvasectomized male participant must agree use reliable contraception sexually active . Subjects ( male female ) childbearing potential must agree use adequate contraception begin sign informed consent form ( ICF ) least 30 day last dose study drug . Willing able comply protocol , include followup visit examination Patients FVC le 30 % predict screening visit . Patients severe airway obstruction Patients unable perform 6 minute walk test Pregnant woman ( i.e . positive serum ßhuman chorionic gonadotropin test sign pregnancy ) , Breast feed woman FRP use reliable contraception recommend Prescriber Guide riociguat pregnancy monitor program Subjects medical disorder , condition , history would impair subject 's ability participate complete study opinion investigator Known significant leave heart disease : Pulmonary venous hypertension indicate baseline pulmonary capillary wedge pressure &gt; 15 mmHg Active state history hemoptysis pulmonary hemorrhage Subjects require nitrate reason Subject use nitrate within one month enter study Pulmonary venoocclusive disease Subjects underlying medical disorder anticipate life expectancy 2 year ( e.g . active cancer disease localize and/or metastasize tumor ) . Subjects hypersensitivity investigational drug excipients . Women pregnant breastfeeding . Severe proven suspect coronary artery disease Clinical relevant hepatic dysfunction indicate : bilirubin &gt; 2 time upper limit normal Visit 0 and/or : alanine aminotransferase ( ALT ) AST aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal Visit 0 and/or : sign severe hepatic insufficiency ( e.g . impaired albumin synthesis albumin &lt; 32 g/L , hepatic encephalopathy &gt; grade 1a ) Visit 0 West Haven Criteria Altered Mental Status Hepatic Encephalopathy Severe renal insufficiency indicate glomerular filtration rate &lt; 30 mL/min Visit 0 , e.g . calculate base Cockcroft formula Modification Diet Renal Disease Study Group ( MDRD ) formula Inability comply protocol and/or willing available followup assessment . Any condition , investigator 's opinion , make subject unsuitable trial participation . Excluded therapy medication , previous concomitant Specific ( e.g . sildenafil tadalafil ) unspecific phosphodiesterase inhibitor ( e.g . dipyridamole , theophylline ) . NO donor ( e.g . nitrate ) . Single application vasoactive drug connection diagnostic vasoreactive testing allow . Concurrent use another investigational drug device therapy ( i.e. , outside study treatment ) , within 4 week trial entry ( sign inform consent form ) . Major surgery within 30 day prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>riociguat</keyword>
	<keyword>saph</keyword>
	<keyword>sarcoidosis</keyword>
	<keyword>sarcoidosis associate pulmonary hypertension</keyword>
</DOC>